Theradiag SA - Asset Resilience Ratio

Latest as of June 2025: 15.59%

Theradiag SA (ALTHE) has an Asset Resilience Ratio of 15.59% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ALTHE total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€1.80 Million
≈ $2.10 Million USD Cash + Short-term Investments

Total Assets

€11.55 Million
≈ $13.50 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2023)

This chart shows how Theradiag SA's Asset Resilience Ratio has changed over time. See Theradiag SA (ALTHE) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Theradiag SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Theradiag SA market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €1.80 Million 15.59%
Total Liquid Assets €1.80 Million 15.59%

Asset Resilience Insights

  • Good Liquidity Position: Theradiag SA maintains a healthy 15.59% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Theradiag SA Industry Peers by Asset Resilience Ratio

Compare Theradiag SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 3.37%
CareRay Digital Medical Technology Co Ltd
SHG:688607
Medical Devices 16.21%
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
Medical Devices 54.67%
Universus Photo Imagings Limited
NSE:UNIVPHOTO
Medical Devices 30.97%
HansBiomed Corporation
KQ:042520
Medical Devices 9.13%
Aligned Genetics Inc
KQ:238120
Medical Devices 2.22%
Heramed Ltd
AU:HMD
Medical Devices 0.83%
Acarix A/S
ST:ACARIX
Medical Devices 37.81%

Annual Asset Resilience Ratio for Theradiag SA (2010–2023)

The table below shows the annual Asset Resilience Ratio data for Theradiag SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 -0.12% €-21.82K
≈ $-25.51K
€18.66 Million
≈ $21.82 Million
-0.34pp
2022-12-31 0.22% €31.10K
≈ $36.36K
€13.94 Million
≈ $16.30 Million
-0.04pp
2021-12-31 0.26% €31.10K
≈ $36.36K
€11.83 Million
≈ $13.83 Million
-0.03pp
2020-12-31 0.29% €31.10K
≈ $36.36K
€10.55 Million
≈ $12.33 Million
0.00pp
2019-12-31 0.30% €31.10K
≈ $36.36K
€10.51 Million
≈ $12.29 Million
-0.03pp
2018-12-31 0.33% €31.10K
≈ $36.36K
€9.56 Million
≈ $11.18 Million
+0.10pp
2017-12-31 0.23% €31.10K
≈ $36.36K
€13.77 Million
≈ $16.10 Million
-33.97pp
2016-12-31 34.19% €5.03 Million
≈ $5.88 Million
€14.71 Million
≈ $17.20 Million
+14.41pp
2015-12-31 19.78% €1.83 Million
≈ $2.14 Million
€9.26 Million
≈ $10.82 Million
+1.29pp
2014-12-31 18.50% €1.53 Million
≈ $1.79 Million
€8.28 Million
≈ $9.69 Million
+17.44pp
2013-12-31 1.06% €31.10K
≈ $36.36K
€2.94 Million
≈ $3.44 Million
+0.08pp
2012-12-31 0.97% €31.10K
≈ $36.36K
€3.20 Million
≈ $3.74 Million
-23.96pp
2011-12-31 24.93% €575.16K
≈ $672.42K
€2.31 Million
≈ $2.70 Million
+24.66pp
2010-12-31 0.27% €10.60K
≈ $12.39K
€3.91 Million
≈ $4.57 Million
--
pp = percentage points

About Theradiag SA

PA:ALTHE France Medical Devices
Market Cap
$33.15 Million
€28.36 Million EUR
Market Cap Rank
#23380 Global
#372 in France
Share Price
€0.48
Change (1 day)
-4.95%
52-Week Range
€0.24 - €0.87
All Time High
€8.20
About

Theraclion SA provides therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize imag… Read more